SEC Comment Letter for PhaseBio Pharmaceuticals Inc (PHASQ) (CIK 0001169245) — Jan 3, 2020
PhaseBio Pharmaceuticals Inc (PHASQ) (CIK 0001169245)
Date: Jan. 3, 2020 · CIK: 0001169245 · Accession: 0000000000-20-000056
AI Filing Summary & Sentiment
File numbers found in text: 333-235735
Letter
January 3, 2020 Jonathan Mow Chief Executive Officer PhaseBio Pharmaceuticals Inc 11260 El Camino Real, Suite 100 San Diego, CA 92130 Re:PhaseBio Pharmaceuticals Inc Registration Statement on Form S-3 Filed December 27, 2019 File No. 333-235735 Dear Mr. Mow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Madison Jones, Esq.
Show Raw Text
January 3, 2020
Jonathan Mow
Chief Executive Officer
PhaseBio Pharmaceuticals Inc
11260 El Camino Real, Suite 100
San Diego, CA 92130
Re:PhaseBio Pharmaceuticals Inc
Registration Statement on Form S-3
Filed December 27, 2019
File No. 333-235735
Dear Mr. Mow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Madison Jones, Esq.